Trials / Completed
CompletedNCT03091920
Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC) in Patients With Stable Type 2 Diabetes and Hypertension
A Phase 2 Study to Compare the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of 2 Dose Regimens of IW-1973 in Patients With Stable Type 2 Diabetes and Hypertension
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Cyclerion Therapeutics · Industry
- Sex
- All
- Age
- 30 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To compare the safety, tolerability, pharmacokinetic (PK) profile, and pharmacodynamic (PD) effects of 2 treatment regimens of IW-1973 tablet (40 mg per day) administered orally for 2 weeks to patients with stable type 2 diabetes mellitus and hypertension.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IW-1973 | Oral Tablet |
| DRUG | Placebo | Oral Tablet |
Timeline
- Start date
- 2017-02-28
- Primary completion
- 2017-08-03
- Completion
- 2017-08-03
- First posted
- 2017-03-27
- Last updated
- 2020-08-31
- Results posted
- 2020-08-31
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03091920. Inclusion in this directory is not an endorsement.